Cargando…

Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis

BACKGROUND: In patients treated with dimethyl fumarate, absolute lymphocyte count decline typically occurs during the first year and then plateaus; early drops have been associated with the development of severe prolonged lymphopenia. OBJECTIVE: We investigated the effect of dimethyl fumarate on abs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buckle, Guy, Bandari, Daniel, Greenstein, Jeffrey, Gudesblatt, Mark, Khatri, Bhupendra, Kita, Mariko, Repovic, Pavle, Riser, Emily, Weinstock-Guttman, Bianca, Thrower, Ben, Loring, Sherrill, Riester, Katherine, Everage, Nick, Prada, Claudia, Koulinska, Irene, Mann, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227148/ https://www.ncbi.nlm.nih.gov/pubmed/32440353 http://dx.doi.org/10.1177/2055217320918619

Ejemplares similares

Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND
por: Repovic, Pavle, et al.
Publicado: (2020)

Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate
por: Lyons, Jennifer, et al.
Publicado: (2022)

Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives
por: Ozel, Osman, et al.
Publicado: (2019)

Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study
por: Wundes, Annette, et al.
Publicado: (2021)

Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry
por: Hellwig, Kerstin, et al.
Publicado: (2021)

Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics
por: Hersh, Carrie M, et al.
Publicado: (2022)

Immune response to vaccines is maintained in patients treated with dimethyl fumarate
por: von Hehn, Christian, et al.
Publicado: (2017)

Dimethyl fumarate for ischemic stroke
por: Kunze, Reiner
Publicado: (2017)

Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes
por: Min, Jinny, et al.
Publicado: (2019)

Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
por: Yao, Yang, et al.
Publicado: (2016)

Effects of dimethyl fumarate on neuroprotection and immunomodulation
por: Albrecht, Philipp, et al.
Publicado: (2012)

Dimethyl fumarate mitigates optic neuritis
por: Zyla, Katarzyna, et al.
Publicado: (2019)

Dimethyl fumarate transfer into human milk
por: Ciplea, Andrea I., et al.
Publicado: (2020)

Drug-Repurposing Strategy for Dimethyl Fumarate
por: Giunta, Salvatore, et al.
Publicado: (2023)

Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study
por: Zivadinov, Robert, et al.
Publicado: (2019)

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
por: Miller, David H., et al.
Publicado: (2015)

Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2015)

Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis
por: Ghadiri, Mahtab, et al.
Publicado: (2017)

Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia
por: Diebold, Martin, et al.
Publicado: (2022)

Dimethyl fumarate for treating Papillon–Lefèvre syndrome
por: Al-Omair, Abdullah, et al.
Publicado: (2022)

The Challenge of Dimethyl Fumarate Repurposing in Eye Pathologies
por: Manai, Federico, et al.
Publicado: (2022)

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials
por: Viglietta, Vissia, et al.
Publicado: (2015)

Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera(®) (Dimethyl Fumarate)
por: Lategan, Thomas W., et al.
Publicado: (2021)

Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets
por: Lundy, Steven K., et al.
Publicado: (2016)

Beneficial actions of the anti-inflammatory dimethyl fumarate in glioblastomas
por: Ghods, Ali J., et al.
Publicado: (2013)

Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes
por: Huang, He, et al.
Publicado: (2015)

Prevention of Autoimmune Diabetes in NOD Mice by Dimethyl Fumarate
por: Li, Shiri, et al.
Publicado: (2021)

Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis
por: Moreira Ferreira, Vanessa F, et al.
Publicado: (2021)

Comparison of dimethyl fumarate and interferon outcomes in an MS cohort
por: Sattarnezhad, Neda, et al.
Publicado: (2022)

Dimethyl Fumarate Induces Glutathione Recycling by Upregulation of Glutathione Reductase
por: Hoffmann, Christina, et al.
Publicado: (2017)

Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance
por: Longbrake, Erin E, et al.
Publicado: (2015)

Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarate
por: Mathias, Amandine, et al.
Publicado: (2017)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
por: Vollmer, Brandi, et al.
Publicado: (2018)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Dimethyl fumarate ameliorates cisplatin-induced renal tubulointerstitial lesions
por: Sasaki, Ayaka, et al.
Publicado: (2019)

Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice
por: Mehta, Devangi, et al.
Publicado: (2019)

Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS
por: Gafson, Arie R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ll2p3r2ni745thsp2p2babd6fl